Poseltinib
Cat. No.: IBDI-435099
Poseltinib, an orally active, selective and irreversible Bruton’s tyrosine kinase (BTK) inhibitor (IC50 =1.95 nM), with 0.3, 2.3 and 2.4-fold selectivity for BTK over BMX, TEC and TXK, respectively. Poseltinib can covalently bind to the active site (cysteine 481 residue) of BTK, and reveales potent inhibition of B cell receptor (BCR), Fc receptor (FcR), Toll-like receptor (TLR) mediated signaling.
Size (Solid + Solvent): 10 mM * 1 mL ready for reconstitution
Online Inquiry
Product Details
| Target |
Btk | BMX Kinase | Toll-like Receptor (TLR) |
| Molecular Weight |
470.52 |
| Appearance |
Solid |
| Synonyms |
HM71224, LY3337641 |
| Purity |
98.01% |
Storage & Handling
| Shipping |
Room temperature in continental US. May vary elsewhere. |
| Storage |
Powder: -20°C/3 years; 4°C/2 years
In solvent: -80°C/6 months; -20°C/1 month |
| Regulatory Status |
This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use. |
! For research use only, not intended for any clinical use.
